Pidotimod
Pidotimod is an immunostimulatory compound often used as an adjuvant. Pidotimod is clinically used to treat acute respiratory tract infections and stimulates both cellular and humoral immunity. In animal models of Toxoplasma infection, pidotimod increases levels of Th1 cytokines and decreases parasite burden, improving survival rates, survival times, and liver histopathology. Pidotimod also promotes maturation of dendritic cells, upregulating expression of CD83 and CD86.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18954239
| Cas No. |
121808-62-6 |
|---|---|
| Purity |
≥98% |
| Formula |
C9H12N2O4S |
| Formula Wt. |
244.27 |
| Chemical Name |
(R)-3-((S)-5-Oxoprolyl)-4-thiazolidinecarboxylic acid |
| IUPAC Name |
(4R)-3-[(2S)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylicacid |
| Synonym |
Axil; Onaka; Pigitil; Polimod |
| Melting Point |
194-198°C |
| Solubility |
Soluble in water (37.8 g/L), methanol (13.8 g/L), ethanol (4.4 g/L), and DMF (72.4g/L). |
| Appearance |
White Crystal Powder |
Zuccotti GV, Mameli C. Pidotimod: the past and the present. Ital J Pediatr. 2013 Dec 6;39:75. PMID: 24314100.
Zhao Y, Huang B, Huang S, et al. Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models. Parasitol Res. 2013 Sep;112(9):3151-60. PMID: 23783399.
Giagulli C, Noerder M, Avolio M, et al. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. Int Immunopharmacol. 2009 Nov;9(12):1366-73. PMID: 19712757.
